Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
| ▸ | ELOC | Q15369 | 1/20 | 0.32 |
| ▸ | ELOB | Q15370 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211033 | 0.91 | USP30 (0.41) | USP30DGAT1MCHR1 | |
| SCHEMBL23211036 | 0.91 | USP30 (0.41) | USP30DGAT1MCHR1 | |
| SCHEMBL30501105 | 0.86 | USP30 (0.37) | USP30DGAT1MCHR1LIPGLPL | |
| SCHEMBL23210879 | 0.85 | USP30 (0.48) | USP30DGAT1AOC3VHLELOC | |
| SCHEMBL29907049 | 0.85 | USP30 (0.48) | USP30DGAT1AOC3VHLELOC | |
| SCHEMBL12539339 | 0.81 | USP30 (0.42) | USP30DGAT1PDGFRBKDRLIPG | |
| SCHEMBL15648371 | 0.80 | USP30 (0.40) | USP30DGAT1MCHR1LIPGLPL | |
| SCHEMBL20338547 | 0.80 | USP30 (0.41) | USP30DGAT1PDGFRBKDRLIPG | |
| SCHEMBL29972963 | 0.80 | USP30 (0.39) | USP30DGAT1PDGFRBKDRLIPG | |
| SCHEMBL27216131 | 0.80 | USP30 (0.39) | USP30DGAT1PDGFRBKDRLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | USP30 4294/4885DGAT1 2962/4885AOC3 4037/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | USP30 4294/4885DGAT1 2962/4885AOC3 4037/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | USP30 4294/4885DGAT1 2962/4885AOC3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.